The FDA granted accelerated approval to Boehringer Ingelheim’s Hernexeos for first-line HER2-mutant NSCLC following a 44-day ...
In today’s Pharma Pulse, the FDA grants a lightning-fast approval for Boehringer’s lung cancer therapy under its new priority program, while CMS Administrator Mehmet Oz launches a sweeping offensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results